ArticleWorld journal of gastrointestinal surgery2025
Survival benefit of primary tumor resection in pancreatic neuroendocrine tumors with unresectable liver metastases: A meta-analysis.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic neuroendocrine tumors (PNETs) are rare malignancies frequently associated with liver metastases (LM). The benefit of primary tumor resection (PTR) in patients with unresectable LM remains controversial. This study evaluates the impact of PTR on overall survival (OS) and tumor grading by integrating evidence from a systematic review, meta-analysis, and Surveillance, Epidemiology, and End Results (SEER) database analysis.
aimTo evaluate the survival benefits of PTR in patients with PNETs and LM.
methodsThis study was conducted in accordance with the PRISMA guidelines. A systematic literature search and meta-analysis were performed using five databases: PubMed, Web of Science, EMBASE, Cochrane Library, and CNKI, with records included up to February 2025. A total of 16 studies (
resultsMeta-analysis results revealed that PTR significantly improved OS in patients with PNETs and LM (hazard ratio = -1.10, 95% confidence interval: -1.43 to -0.71,
conclusionPTR significantly improves OS in PNET patients with LM. However, its effect on tumor grading remains unclear, warranting further prospective studies to refine surgical strategies for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.